Vaccines Market Size, Share, Industry & Growth Analysis by 2027

    Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), Dengue, Cytomegalovirus (CMV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients) and Geography

    Publication Month: Oct 2020 | Report Code: TIPRE00015468 | No. of Pages: 207 | Category: Pharmaceuticals | Status: Published

    The Vaccines in healthcare market was valued at US$ 36,998.8 million in 2018 and it is projected to reach US$ 64,538.4 million by 2027; it is expected to grow at a CAGR of 6.5% from 2019 to 2027. A

    vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. The growth of the Vaccines in healthcare market is attributed to the rising prevalence of infectious diseases, growing focus on immunization programs, and increasing support for vaccine development are expected to boost the market growth over the years. However, soaring prices of the vaccines and complexity and cost of vaccine manufacturing are likely to pose a negative impact on the market growth.

    The Vaccines in healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

    Lucrative Regions for Vaccines in Healthcare Market
    Lucrative Regions for Vaccines in Healthcare Market

    Get more information on this report :


    Market Insights

    Growing Applications of Vaccines in Healthcare to Drive Vaccines in Healthcare Market Growth

    In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These emerging infectious diseases are a burden on public health but have also an impact on global economies. The new diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C). The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress. Furthermore, the Asia Pacific region suffers from a number of global disease like influenza, dengue, tuberculosis, and pneumonia, are endemic to the entire region, and at the same time there are the newly emerging Hendra and Nipah viruses. South East Asian nations are in the transitional stage where the traditional infectious diseases (diarrhea and pneumonia) co-occur with non-infectious diseases (cardiovascular diseases, diabetes). Approximately 33.33% of the world's child deaths occur in the South East Asian countries. 75% of these deaths are due to diarrhea or pneumonia diseases. In developed countries, the cases of infectious diseases has decreased in the past decade, but there has been a rise of re-emerging diseases worldwide, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), measles, avian and pandemic influenza, chikungunya virus, Ebola virus disease (EVD) and Zika virus disease, which has attracted a renewed focus on infectious diseases around the developed countries. Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.

    According to the estimates from UNICEF, WHO, World Bank, and the UN Population Division, in the last decade, more than 5 million deaths were reduced with the help of vaccinations delivered around the world. Immunization is considered to be one of the most cost-effective ways to tackle public health challenges. In the past decade, the scope of immunization has expanded significantly as new vaccines and delivery technologies have been introduced into routine immunization programs worldwide. At the same time it has witnessed a proliferation of factors at the global stage that promote immunization and it has enabled the vaccines to all parts of the world.

    Nations all around the world are witnessing broad demographic and economic changes. Already, there are more people living in middle-income countries than in low income countries. Increased economic stability will provide countries more ownership over their immunization programs, and countries will require more specialized technical assistance to make decisions and address problems. More countries will have sufficient capacity for medicines regulation and will be less reliant on WHO’s prequalification process at the global level. Health indicators will be broader, encompassing communicable and non-communicable diseases as well as emerging burdens related to climate change, increased travel and trade, and new infectious and vector-borne diseases. Prevention will continue to be important, and attention will continue to be directed to interventions that are considered cost-effective. More vaccines will be available to protect against more diseases throughout the human life course. Immunization will likely become part of an integrated package of disease prevention strategies, meaning that immunization services will be accompanied by other services and delivered in more places, including schools, homes, and pharmacies. For instance, The Pulse Polio Initiative in India was started in 1995 with an objective to eradicate polio completely with administration of Oral Polio Vaccine to the children in the age group of 0-5 years. According to the Ministry of Health and Family Welfare (MoHFW), Government of India, around 172 million children are immunized each year with polio drops vaccine on National Immunization Day (NID) during National and Sub-national immunization rounds (in high risk areas). The increasing focus on immunization programs is likely to foster the growth of market in the coming years.

    In addition to the funds from traditional research-funding institutions, the Gates Foundation has invested hundreds of millions of dollars in R&D of new vaccines against the leading killers of children and adults everywhere. GAVI has established public-private partnerships to accelerate late-stage development and introduction of priority vaccines against diseases such as rotavirus and pneumococcus. These partnerships are designed to work with governments, donors, and industry to streamline demand, supply, and financing decisions. They coordinate and fund the efforts of partners supporting national decision makers whether to introduce these new products, ensuring a reliable and sustainable supply of affordable vaccine to developing countries, and reducing risks and creating incentives for private investment to ensure access to the product.

    The U.S. Department of Health and Human Services has funded USD 81 million for developing vaccines to fight Zika virus. Furthermore, TRANSVAC is a new infrastructure project - funded by the European Commission in the context of Horizon 2020 - that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal to build an efficient and sustainable collaboration of experts and facilities to catalyse vaccine research in Europe. TRANSVAC offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.

    Global Vaccine Fund commits $150 Million in vaccines and funding over five years to 13 developing countries. Countries will receive financial and technical assistance in order to strengthen basic immunization systems and to introduce newer, under-used vaccines such as hepatitis B and Haemophilus influenzae type b (Hib). Some countries will receive support in both areas. Thus the growing support for vaccine development is likely to favor market growth.

    Technology-Based Insights

    In terms of technology, the Vaccines in healthcare market is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, inactivated and subunit vaccines, and toxoid vaccines In 2018, the conjugate vaccines segment held a largest market share of 65.1% of the vaccines market, By Technology.

    Vaccines in Healthcare Market, by Technology – 2018 and 2027
    Vaccines in Healthcare Market, by Technology – 2018 and 2027

    Get more information on this report :



    Disease Indication-Based Insights

    In terms of disease indication, the Vaccines in healthcare market is segmented into dtp (diphtheria tetanus toxoids and pertussis), influenza, hepatitis, respiratory syncytial virus (rsv), and other diseases. In 2018, the others segment held a largest market share of 59.7% of the vaccines market, by disease indication segment.

    Route of Administration-Based Insights

    Based on route of administration, the Vaccines in healthcare market is segmented into oral, injectable, and other routes of administration. In 2018, the injectable segment held a largest market share of 48.7% of the vaccines market, by route of administration.

    Patient Type-Based Insights

    In terms of patient type, the Vaccines in healthcare market is segmented into pediatric patients, and adults. In 2018, the paediatric segment held a largest market share of 70.0% of the vaccines market, by patient type.

    Strategic Insights

    The Vaccines in healthcare market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

    Vaccines in Healthcare Market – by Technology

    • Recombinant vaccines
    • Conjugate Vaccines
    • Live Attenuated Vaccines
    • Inactivated Vaccines
    • Toxoid Vaccines

    Vaccines in Healthcare Market – by Disease Indication

    • DTP (diphtheria, tetanus, and pertussis)
    • Influenza
    • Hepatitis
    • Respiratory Syncytial Virus (RSV)
    • Other Diseases

    Vaccines in Healthcare Market – by Route of Administration

    • Oral
    • Injectable
    • Other

    Vaccines in Healthcare Market – by Patient Type

    • Adults
    • Pediatric

    Vaccines in Healthcare Market – by Geography

    • North America
      • US
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • UK
      • Spain
      • Rest of Europe
    • Asia Pacific (APAC)
      • China
      • India
      • South Korea
      • Japan
      • Australia
      • Rest of APAC
    • Middle East & Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of MEA
    • South America and Central America (SCAM)
      • Brazil
      • Argentina
      • Rest of SCAM

    Company Profiles

    • Bavarian Nordic
    • PFIZER INC
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Panacea Biotec Limited
    • Astellas Pharma Inc.
    • NOVAVAX, INC.
    • VBI Vaccines Inc.

    1. Introduction

    1.1 Scope Of The Study

    1.2 The Insight Partners Research Report Guidance

    1.3 Market Segmentation

    1.3.1 Global Vaccines Market – By Technology

    1.3.2 Global Vaccines Market – By Disease Indication

    1.3.3 Global Vaccines Market – By Route of Administration

    1.3.4 Global Vaccines Market – By Patient Type

    1.3.5 Global Vaccines Market – By Geography

    2. Vaccines Market – Key Takeaways

    3. Research Methodology

    3.1 Coverage

    3.2 Secondary Research

    3.3 Primary Research

    4. Global Vaccines Market – Market Landscape

    4.1 Overview

    4.2 Pest Analysis

    4.2.1 North America – PEST Analysis

    4.2.2 Europe– PEST Analysis

    4.2.3 Asia Pacific– PEST Analysis

    4.2.4 Middle East & Africa– PEST Analysis

    4.2.5 South and Central America – PEST Analysis

    4.3 Expert Opinions

    5. Global Vaccines Market – Key Market Dynamics

    5.1 Key Market Drivers

    5.1.1 Rising Prevalence of Infectious Diseases

    5.1.2 Growing Focus on Immunization Programs

    5.1.3 Increasing Support for Vaccine Development

    5.2 Key Market Restraints

    5.2.1 The Complexity And Cost of Vaccine Manufacturing

    5.2.2 Soaring Costs of Vaccines

    5.3 Key Market Opportunities

    5.3.1 Robust Pipeline of Vaccines

    5.4 Future Trends

    5.4.1 New Vaccine Delivery Systems

    5.5 Impact Analysis

    6. Vaccines Market – Global Analysis

    6.1 Global Vaccines Market Revenue Forecasts And Analysis

    6.2 Global Vaccines Market, By Geography - Forecasts And Analysis

    6.3 Performance Of Key Players

    6.3.1 GlaxoSmithKline plc

    6.3.2 Sanofi

    7. Vaccines Market - Technology

    7.1 Overview

    7.2 Vaccines Market Share, Technology, 2019 And 2027 (%)

    7.3 Recombinant Vaccinesinant Vaccines

    7.3.1 Overview

    7.3.2 Recombinant Vaccinesinant Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    7.4 Conjugate Vaccines

    7.4.1 Overview

    7.4.2 Conjugate Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    7.5 Live Attenuated Vaccines Attenuated Vaccines

    7.5.1 Overview

    7.5.2 Live Attenuated Vaccines Attenuated Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    7.6 Inactivated and Subunit Vaccines Vaccines

    7.6.1 Overview

    7.6.2 Inactivated and Subunit Vaccines Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    7.7 Toxoid Vaccines Vaccines

    7.7.1 Overview

    7.7.2 Toxoid Vaccines Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    8. Vaccines Market– Disease Indication

    8.1 Overview

    8.2 Disease Indication Market Revenue And Forecasts Analysis (Us$ Mn)

    8.3 Dtp (Diphtheria, Tetanus, And Pertussis)

    8.3.1 Overview

    8.3.2 DTP (Diphtheria, Tetanus, And Pertussis): Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    8.4 Influenza

    8.4.1 Overview

    8.4.2 Influenza: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)

    8.5 Dengue

    8.5.1 Overview

    8.5.2 Dengue: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)

    8.6 Cytomegalovirus (CMV)

    8.6.1 Overview

    8.6.2 Cytomegalovirus (CMV): Vaccines Market -Revenue and Forecast to 2027 (US$ Million)

    8.7 Hepatitis

    8.7.1 Overview

    8.7.2 Hepatitis: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    8.7.3 Hepatitis A

    8.7.3.1 Overview

    8.7.3.2 Hepatitis A: Hepatitis Market - Revenue and Forecast to 2027 (US$ Million)

    8.7.4 Hepatitis B

    8.7.4.1 Overview

    8.7.4.2 Hepatitis B: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    8.8 Respiratory Syncytial Virus (Rsv)

    8.8.1 Overview

    8.8.2 Respiratory Syncytial Virus (RSV): Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    8.9 Other Diseases

    8.9.1 Overview

    8.9.2 Other Diseases: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)

    9. Vaccines Market– Route Of Administration

    9.1 Overview

    9.2 Route Of Administration Market Revenue And Forecasts Analysis (Us$ Mn)

    9.3 Oral

    9.3.1 Overview

    9.3.2 Oral: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    9.4 Injectable

    9.4.1 Overview

    9.4.2 Injectable: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)

    9.5 Other Routes Of Administrations

    9.5.1 Overview

    9.5.2 Other Routes of Administration; Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    10. Vaccines Market– Patient Type

    10.1 Overview

    10.2 Patient Type Market Revenue And Forecasts Analysis (Us$ Mn)

    10.3 Paediatric

    10.3.1 Overview

    10.3.2 Pediatric: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    10.4 Adults Market

    10.4.1 Overview

    10.4.2 Adults: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

    11. Vaccines Market– Geographical Analysis

    11.1 North America: Vaccines Market

    11.1.1 Overview

    11.1.2 North America: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.1.3 North America: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.1.4 North America: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.1.4.1 North America: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.1.5 North America: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.1.6 North America: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.1.7 North America: Vaccines Market, By Country, 2019 & 2027 (%)

    11.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.1.8.1 US: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.1.8.2 US: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.1.8.2.1 US: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.1.8.3 US: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.1.8.4 US: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.1.9 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.1.9.1 Canada: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.1.9.2 Canada: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.1.9.3 Canada: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.1.9.3.1 Canada: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.1.9.4 Canada: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.1.9.5 Canada: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.1.10 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.1.10.1 Mexico: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.1.10.2 Mexico: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.1.10.3 Mexico: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.1.10.3.1 Mexico: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.1.10.4 Mexico: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.1.10.5 Mexico: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2 Europe: Vaccines Market

    11.2.1 Overview

    11.2.2 Europe: Vaccines Market Revenue, by Country (2019) (US$ Mn)

    11.2.3 Europe: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.4 Europe: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.5 Europe: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.5.1 Europe: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.6 Europe: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.7 Europe: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2.8 Europe: Vaccines Market, By Country, 2019 & 2027 (%)

    11.2.9 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.2.9.1 Germany: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.9.2 Germany: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.9.3 Germany: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.9.3.1 Germany: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.9.4 Germany: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.9.5 Germany: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2.10 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.2.10.1 UK: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.10.2 UK: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.10.3 UK: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.10.3.1 UK: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.10.4 UK: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.10.5 UK: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2.11 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.2.11.1 France: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.11.2 France: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.11.3 France: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.11.3.1 France: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.11.4 France: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.11.5 France: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2.12 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.2.12.1 Italy: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.12.2 Italy: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.12.3 Italy: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.12.3.1 Italy: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.12.4 Italy: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.12.5 Italy: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.2.13 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.2.13.1 Spain: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.2.13.2 Spain: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.2.13.3 Spain: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.2.13.3.1 Spain: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.2.13.4 Spain: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.2.13.5 Spain: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3 Asia Pacific Vaccines Market

    11.3.1 Overview

    11.3.2 Asia Pacific: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.3 Asia Pacific: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.4 Asia Pacific: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.4.1 Asia Pacific: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.5 Asia Pacific: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.6 Asia Pacific: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3.7 Asia Pacific: Vaccines Market, By Country, 2018 & 2027 (%)

    11.3.8 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.3.8.1 China: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.8.2 China: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.8.3 China: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.8.3.1 China: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.8.4 China: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.8.5 China: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3.9 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.3.9.1 Japan: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.9.2 Japan: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.9.3 Japan: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.9.3.1 Japan: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.9.4 Japan: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.9.5 Japan: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3.10 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.3.10.1 India: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.10.2 India: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.10.3 India: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.10.3.1 India: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.10.4 India: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.10.5 India: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3.11 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.3.11.1 Australia: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.11.2 Australia: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.11.3 Australia: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.11.3.1 Australia: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.11.4 Australia: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.11.5 Australia: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.3.12 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.3.12.1 South Korea: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.3.12.2 South Korea: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.3.12.3 South Korea: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.3.12.3.1 South Korea: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.3.12.4 South Korea: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.3.12.5 South Korea: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.4 Middle East & Africa Vaccines Market

    11.4.1 Middle East And Africa: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.4.2 Middle East and Africa: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.4.3 Middle East and Africa: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.4.3.1 Middle East and Africa: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.4.4 Middle East and Africa: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.4.5 Middle East and Africa: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.4.6 Middle East & Africa: Vaccines Market, By Country, 2019 & 2027 (%)

    11.4.7 UAE Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.4.7.1 UAE: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.4.7.2 UAE: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.4.7.3 UAE: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.4.7.3.1 UAE: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.4.7.4 UAE: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.4.7.5 UAE: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.4.8 Saudi Arabia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.4.8.1 Saudi Arabia: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.4.8.2 Saudi Arabia: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.4.8.3 Saudi Arabia: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.4.8.3.1 Saudi Arabia: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.4.8.4 Saudi Arabia: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.4.8.5 Saudi Arabia: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.4.9 South Africa Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.4.9.1 South Africa: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.4.9.2 South Africa: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.4.9.3 South Africa: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.4.9.3.1 South Africa: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.4.9.4 South Africa: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.4.9.5 South Africa: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.5 South And Central America Vaccines Market

    11.5.1 Overview

    11.5.2 South and Central America: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.5.3 South and Central America: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.5.4 South and Central America: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.5.4.1 South and Central America: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.5.5 South and Central America: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.5.6 South and Central America: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.5.7 South and Central America: Vaccines Market, by Country, 2019 and 2027 (%)

    11.5.8 Brazil Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.5.8.1 Brazil: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.5.8.2 Brazil: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.5.8.3 Brazil: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.5.8.3.1 Brazil: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.5.8.4 Brazil: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.5.8.5 Brazil: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    11.5.9 Argentina Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

    11.5.9.1 Argentina: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)

    11.5.9.2 Argentina: Vaccines Market, By Technology, 2018-2027 (USD Million)

    11.5.9.3 Argentina: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)

    11.5.9.3.1 Argentina: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)

    11.5.9.4 Argentina: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)

    11.5.9.5 Argentina: Vaccines Market, By Patient Type, 2018-2027 (USD Million)

    12. Impact Of Covid-19 Pandemic On Global Vaccines Market

    12.1 North America: Impact assessment of COVID-19 Pandemic

    12.2 Europe: Impact assessment of COVID-19 Pandemic

    12.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic

    12.4 Rest of World: Impact assessment of COVID-19 Pandemic

    13. Vaccines Market – Industry Landscape

    13.1 Overview

    13.2 Growth Strategies Done By The Companies In The Market, (%)

    13.3 Organic Developments

    13.3.1 Overview

    13.4 Inorganic Developments

    13.4.1 Overview

    14. Vaccines Market –Key Company Profiles

    14.1 Pfizer Inc.

    14.1.1 Key Facts

    14.1.2 Business Description

    14.1.3 Financial Overview

    14.1.4 Product Portfolio

    14.1.5 SWOT Analysis

    14.1.6 Key Developments

    14.2 Glaxosmithkline Plc.

    14.2.1 Key Facts

    14.2.2 Business Description

    14.2.3 Financial Overview

    14.2.4 Product Portfolio

    14.2.5 SWOT Analysis

    14.2.6 Key Developments

    14.3 Merck & Co., Inc.

    14.3.1 Key Facts

    14.3.2 Business Description

    14.3.3 Financial Overview

    14.3.4 Product Portfolio

    14.3.5 SWOT Analysis

    14.3.6 Key Developments

    14.4 Sanofi

    14.4.1 Key Facts

    14.4.2 Business Description

    14.4.3 Financial Information

    14.4.4 Product Portfolio

    14.4.5 SWOT Analysis

    14.4.6 Key Developments

    14.5 Johnson & Johnson Services, Inc.

    14.5.1 Key Facts

    14.5.2 Business Description

    14.5.3 Financial Overview

    14.5.4 Product Portfolio

    14.5.5 SWOT Analysis

    14.5.6 Key Developments

    14.6 Panacea Biotec Limited

    14.6.1 Key Facts

    14.6.2 Business Description

    14.6.3 Financial Information

    14.6.4 Product Portfolio

    14.6.5 SWOT Analysis

    14.6.6 Key Developments

    14.7 Astellas Pharma Inc.

    14.7.1 Key Facts

    14.7.2 Business Description

    14.7.3 Financial Overview

    14.7.4 Product Portfolio

    14.7.5 Swot Analysis

    14.7.6 Key Developments

    14.8 Novavax, Inc.

    14.8.1 Key Facts

    14.8.2 Business Description

    14.8.3 Financial Information

    14.8.4 Product Pipeline

    14.8.5 SWOT Analysis

    14.8.6 Key Developments

    14.9 Vbi Vaccines Inc.

    14.9.1 Key Facts

    14.9.2 Business Description

    14.9.3 Financial Information

    14.9.4 Product Portfolio

    14.9.5 SWOT Analysis

    14.9.6 Key Developments

    14.10 Bavarian Nordic

    14.10.1 Key Facts

    14.10.2 Business Description

    14.10.3 Financial Information

    14.10.4 Product Pipeline

    14.10.5 SWOT Analysis

    14.10.6 Key Developments

    15. Appendix

    15.1 About The Insight Partners

    15.2 Glossary Of Terms

    LIST OF TABLES

    Table 1. North America Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 2. North America: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 3. North America: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 4. North America: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 5. North America: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 6. US Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 7. US: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 8. US: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 9. US: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 10. US: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 11. Canada Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 12. Canada: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 13. Canada: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 14. Canada: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 15. Canada: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 16. Mexico Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 17. Mexico: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 18. Mexico: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 19. Mexico: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 20. Mexico: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 21. Europe Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 22. Europe: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 23. Europe: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 24. Europe: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 25. Europe: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 26. Germany Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 27. Germany: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 28. Germany: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 29. Germany: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 30. Germany: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 31. UK Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 32. UK: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 33. UK: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 34. UK: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 35. UK: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 36. France Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 37. France: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 38. France: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 39. France: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 40. France: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 41. Italy Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 42. Italy: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 43. Italy: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 44. Italy: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 45. Italy: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 46. Spain Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 47. Spain: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 48. Spain: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 49. Spain: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 50. Spain: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 51. Asia Pacific Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 52. Asia Pacific: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 53. Asia Pacific: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 54. Asia Pacific: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 55. Asia Pacific: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 56. China Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 57. China: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 58. China: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 59. China: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 60. China: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 61. Japan Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 62. Japan: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 63. Japan: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 64. Japan: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 65. Japan: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 66. India Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 67. India: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 68. India: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 69. India: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 70. India: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 71. Australia Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 72. Australia: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 73. Australia: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 74. Australia: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 75. Australia: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 76. South Korea Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 77. South Korea: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 78. South Korea: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 79. South Korea: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 80. South Korea: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 81. Middle East and Africa Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 82. Middle East and Africa: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 83. Middle East and Africa: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 84. Middle East and Africa: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 85. Middle East and Africa: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 86. UAE Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 87. UAE: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 88. UAE: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 89. UAE: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 90. UAE: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 91. Saudi Arabia Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 92. Saudi Arabia: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 93. Saudi Arabia: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 94. Saudi Arabia: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 95. Saudi Arabia: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 96. South Africa Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 97. South Africa: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 98. South Africa: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 99. South Africa: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 100. South Africa: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 101. South and Central America Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 102. South and Central America: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 103. South and Central America: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 104. South and Central America: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 105. South and Central America: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 106. Brazil Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 107. Brazil: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 108. Brazil: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 109. Brazil: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 110. Brazil: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 111. Argentina Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)

    Table 112. Argentina: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)

    Table 113. Argentina: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)

    Table 114. Argentina: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)

    Table 115. Argentina: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)

    Table 116. Organic Developments Done By Companies

    Table 117. Inorganic developments done by Companies

    Table 118. Glossary of Terms, vaccines market

    LIST OF FIGURES

    Figure 1. Vaccines Market Segmentation

    Figure 2. Vaccines Segmentation, By Region

    Figure 3. Vaccines Market Overview

    Figure 4. Conjugate VAccines technology Segment Held Largest Share of vaccines Market

    Figure 5. APAC to Show Significant Growth During Forecast Period

    Figure 6. Vaccines Market, by Geography (US$ Million)

    Figure 7. Global VAccines Market – Leading Country Markets (US$ Million)

    Figure 8. Global Vaccines Market, Industry Landscape

    Figure 9. North America PEST Analysis

    Figure 10. Europe PEST Analysis

    Figure 11. Asia pacific PEST Analysis

    Figure 12. Middle East & Africa PEST Analysis

    Figure 13. South and central america PEST Analysis

    Figure 14. vaccines market impact analysis of driver and restraints

    Figure 15. global Vaccines market – Revenue Forecasts and Analysis –2019- 2027

    Figure 16. global Vaccines market – by geography Forecasts and Analysis – 2019- 2027

    Figure 17. Vaccines Market Share, Technology, 2019 and 2027 (%)

    Figure 18. Recombinant Vaccinesinant Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)

    Figure 19. Conjugate Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)

    Figure 20. Live Attenuated Vaccines Attenuated Vaccines: Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)

    Figure 21. Inactivated and Subunit Vaccines Vaccines: Vaccines Market- Revenue And Forecasts to 2027 (US$ Million)

    Figure 22. Toxoid Vaccines Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)

    Figure 23. Disease Indication MARKET Analysis and Forecasts 2019 and 2027 (%)

    Figure 24. DTP (Diphtheria, Tetanus, And Pertussis): Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)

    Figure 25. Influenza: Vaccines Market- Revenue And Forecasts to 2027 (US$ Million)

    Figure 26. Dengue: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 27. Cytomegalovirus (CMV): Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 28. Hepatitis: Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)

    Figure 29. Hepatitis A: Hepatitis Market -Revenue And Forecasts To 2027 (US$ Million)

    Figure 30. Hepatitis B: Vaccines Market -Revenue And Forecasts to 2027 (US$ Million)

    Figure 31. Respiratory Syncytial Virus (RSV): Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)

    Figure 32. Other Diseases: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 33. route of administration MARKET Analysis and Forecasts 2019 and 2027 (%)

    Figure 34. Oral: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 35. Injectable: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 36. Other Routes Of Administration: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 37. patient type MARKET Analysis and Forecasts 2019 and 2027 (%)

    Figure 38. Pediatric: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 39. Adults: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)

    Figure 40. North America: Vaccines Market, By Country (2019) (usD Million)

    Figure 41. North America Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 42. North America: Vaccines Market, By Country, 2019& 2027 (%)

    Figure 43. US Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 44. Canada Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 45. Mexico Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 46. Europe Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 47. Europe: Vaccines Market, By Country, 2019 & 2027 (%)

    Figure 48. Germany Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 49. UK Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 50. France Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 51. Italy Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 52. Spain Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 53. Asia Pacific Vaccines market revenue Overview, by Country (2019) (us $ mn)

    Figure 54. Asia Pacific Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 55. Asia Pacific: Vaccines Market, By Country, 2018 & 2027 (%)

    Figure 56. China Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 57. Japan Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 58. India Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 59. Australia Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 60. South Korea Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 61. Middle East & Africa Vaccines market REVENUE, by Country, 2019 (US$ MN)

    Figure 62. Middle East and Africa Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 63. Middle East & Africa: Vaccines Market, By Country, 2019 & 2027 (%)

    Figure 64. UAE Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 65. Saudi Arabia Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 66. South Africa Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 67. South and Central America Vaccines market REVENUE, by Country, 2019 (US$ MN)

    Figure 68. South and Central America Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 69. South and Central America: Vaccines Market, by Country, 2019 and 2027 (%)

    Figure 70. Brazil Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 71. Argentina Vaccine Market Revenue And Forecasts to 2027 (US$ Million)

    Figure 72. IMPACT OF COVID-19 PANDEMIC IN NORTH AMERICAN COUNTRY MARKETS

    Figure 73. IMPACT OF COVID-19 PANDEMIC IN EUROPE COUNTRY MARKETS

    Figure 74. IMPACT OF COVID-19 PANDEMIC IN ASIA-PACIFIC COUNTRY MARKETS

    Figure 75. IMPACT OF COVID-19 PANDEMIC IN REST OF WORLD COUNTRY MARKETS

    Figure 76. Growth Strategies done by the companies in the Market, (%)

    The List of Companies - Vaccines Market

    1. PFIZER INC
    2. GlaxoSmithKline plc.
    3. Merck & Co., Inc.
    4. Sanofi
    5. Johnson & Johnson Services, Inc
    6. Panacea Biotec Limited
    7. AstellasPharma Inc.
    8. NOVAVAX, INC.
    9. VBI Vaccines Inc.
    10. Bavarian Nordic
    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccinesmarket.
    • Highlights key business priorities in order to assist companies to realign their business strategies.
    • The key findings and recommendations highlight crucial progressive industry trends in the global vaccinesmarket, thereby allowing players across the value chain to develop effective long-term strategies.
    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
    TIPRE00015468
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market



    Frequently Asked Questions

    A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
    The growth of the market is attributed to the rising prevalence of infectious diseases, growing focus on implementation of immunization programs, and increasing support for vaccine development.
    Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, Sanofi, Johnson & Johnson Services, Inc., Panacea Biotec Limited, Astellas Pharma Inc., NOVAVAX, INC., VBI Vaccines Inc., and Bavarian Nordic are some of the major players in the vaccines market.

    Pricing
    • $2000
    • $4500 $3640
    • $6500 $5240
    • $8500 $6840

        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount   Speak to Analyst